New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.95-2.46 (-14.99%)
At close: 04:00PM EDT
14.00 +0.05 (+0.36%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 573.73M
Enterprise value 882.81M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.14
Price/book (mrq)44.19
Enterprise value/revenue 2.39
Enterprise value/EBITDA -30.84

Trading information

Stock price history

Beta (5Y monthly) 1.09
52-week change 3-6.69%
S&P500 52-week change 3-16.62%
52-week high 321.25
52-week low 310.81
50-day moving average 316.49
200-day moving average 315.97

Share statistics

Avg vol (3-month) 31.09M
Avg vol (10-day) 31.73M
Shares outstanding 541.13M
Implied shares outstanding 6N/A
Float 826.11M
% held by insiders 13.30%
% held by institutions 173.00%
Shares short (14 Sept 2022) 44.96M
Short ratio (14 Sept 2022) 44.93
Short % of float (14 Sept 2022) 415.28%
Short % of shares outstanding (14 Sept 2022) 412.05%
Shares short (prior month 14 Aug 2022) 411.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin -17.54%
Operating margin (ttm)-11.80%

Management effectiveness

Return on assets (ttm)-5.32%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)368.89M
Revenue per share (ttm)12.23
Quarterly revenue growth (yoy)5.20%
Gross profit (ttm)360.37M
EBITDA -41.78M
Net income avi to common (ttm)-70.32M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)404.78M
Total cash per share (mrq)13.58
Total debt (mrq)717M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.22
Book value per share (mrq)-12.41

Cash flow statement

Operating cash flow (ttm)2.78M
Levered free cash flow (ttm)6.76M